1306763-71-2

Usage

Uses

Used in Pharmaceutical Industry:
(R)-tert-butyl (4-(5-(3-cyanophenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate is used as a therapeutic agent for cognitive dysfunction. It targets PDE9A, an enzyme linked to cognitive impairments in neurodegenerative diseases, and has shown promising results in preclinical studies.
Used in Research and Development:
(R)-tert-butyl (4-(5-(3-cyanophenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate is also used in the research and development of novel treatments for cognitive impairment and neurodegenerative diseases. Its selective inhibition of PDE9A makes it a valuable tool for studying the enzyme's role in brain function and the potential for developing new therapeutic strategies.
Used in Drug Design and Synthesis:
The unique structure of (R)-tert-butyl (4-(5-(3-cyanophenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate, including its carbamate group and oxadiazole ring, makes it a valuable compound for drug design and synthesis. Researchers can use this structure as a starting point for developing new PDE9A inhibitors or other related compounds with potential applications in treating cognitive impairments and neurodegenerative diseases.

Upstream product

• 1306763-30-3 (R)-tert-butyl 4-cyano-2,3-dihydro-1H-inden-1-ylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1306763-32-5 (R)-tert-butyl 4-(N-hydroxycarbamimidoyl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1306763-28-9 (R)-N-((R)-4-cyano-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide 
• 1306763-29-0 (R)-(1-amino-2,3-dihydro-1H-indene-1-yl)-4-carbonitrile hydrochloride 
• 60899-34-5 4-cyano-2,3-dihydro-1H-inden-1-one 
• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 
• 1306763-27-8 (R)-N-(4-cyano-2,3-dihydro-1H-indene-1-ylidene)-2-methylpropane-2-sulfinamide 
• 1306763-24-5 (R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile 

Relevant academic research and scientific papers

Enantioselective Synthesis of Ozanimod, the Active Pharmaceutical Ingredient of a New Drug for Multiple Sclerosis

We report here a short enantioselective synthesis of Ozanimod, a potent modulator of the enzyme Sphingosine-1-phosphate receptor (S1PR), recently approved by FDA and EMA for the treatment of relapsing-remitting multiple sclerosis. Amongst different synthetic approaches explored, we achieved the best result introducing the stereogenic centre in the last step through imine asymmetric transfer hydrogenation (ATH) using Wills’ catalysts. Besides the reduced numbers of enantiomeric purity controls required, this process culminates in an exceptionally high enantioselective reductive amination obtained with commercially available tethered Ru catalysts. Starting from commercially available 4-cyano-indanone, enantiomerically pure Ozanimod was obtained in 5 steps in 62 % overall yield and 99 % ee.

COMPOUNDS AND METHODS FOR TREATING LUPUS

Methods for treatment of systemic lupus erythematosus (SLE" or "Lupus") by administration of a modulator of sphingosine-1-phosphate receptor subtype 1 (S1P1), as well as compositions and methods related to the same, wherein such S1P1 modulators have the f

SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided, including compounds which modulate subtype 1 of the S1P receptor, and methods of their therapeutic and/or prophylactic use in combination with at least one other medicament adapted for treatement of a malcondition for which activation of S1P1 is medically indicated, such as multiple sclerosis.